This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
International Flavors (IFF) Q2 Earnings Top on Higher Volumes
by Zacks Equity Research
International Flavors (IFF) reports volume growth in high-single digits in second-quarter 2024. The company expects 2024 sales to be in the range of $11.1-$11.3 billion.
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
by Kinjel Shah
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Stock Market News for May 8, 2024
by Zacks Equity Research
Wall Street ended mixed on Tuesday as investors eagerly awaited signals from the Federal Reserve regarding potential interest rate cuts.
Why Kenvue (KVUE) Could Beat Earnings Estimates Again
by Zacks Equity Research
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Company News for Dec 20, 2023
by Zacks Equity Research
Companies in The News Are: BA, DLAKY, KVUE, INTC, SHEL
J&J (JNJ) Announces 2024 and Long-Term Financial Outlook
by Zacks Equity Research
J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.
JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus
by Sweta Killa
The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
by Zacks Equity Research
J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
by Zacks Equity Research
With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.
Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now
by Zacks Equity Research
J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.
Factors to Note Ahead of Hain Celestial's (HAIN) Q4 Earnings
by Zacks Equity Research
Hain Celestial's (HAIN) fourth-quarter fiscal 2023 performance is likely to reflect the adverse impact of weakness in the North America segment and a high inflationary environment.